Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting

Seminars in Cancer Biology

Volumn 20, Issue 6, 2010, Pages 424-430

  Burger, Jan A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemokine receptors; Chemokines; CLL; CXCR4; Plerixafor

Indexed keywords

ALEMTUZUMAB; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; CAL 101; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR5; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; FOSTAMATINIB; INTERLEUKIN 8; LUMILIXIMAB; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OFATUMUMAB; PCI 32765; PLERIXAFOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BONE MARROW; CANCER RESEARCH; CELL INTERACTION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKEMIA CELL; LYMPHOID ORGAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; CHEMOKINES; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; RECEPTORS, CHEMOKINE;

EID: 78649786160     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.09.005     Document Type: Review

References (98)

1. Thelen M., Peveri P., Kernen P., von Tscharner V., Walz A., Baggiolini M. Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB Journal 1988, 2:2702-2706.
2. Kunkel S.L., Strieter R.M., Lindley I.J., Westwick J. Chemokines: new ligands, receptors and activities. Immunology Today 1995, 16:559-561.
3. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
4. Loetscher P., Moser B., Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Advances in Immunology 2000, 74:127-180.
5. Butcher E.C., Picker L.J. Lymphocyte homing and homeostasis. Science (New York, NY) 1996, 272:60-66.
6. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
7. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nature Immunology 2001, 2:123-128.
8. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Reviews. Immunology 2009, 9:618-629.
9. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
10. Campbell J.J., Hedrick J., Zlotnik A., Siani M.A., Thompson D.A., Butcher E.C. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science (New York, NY) 1998, 279:381-384.
11. Burger J.A., Burger M., Kipps T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94:3658-3667.
12. Mohle R., Failenschmid C., Bautz F., Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999, 13:1954-1959.
13. Durig J., Schmucker U., Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001, 15:752-756.
14. Barretina J., Junca J., Llano A., Gutierrez A., Flores A., Blanco J., et al. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Annals of Hematology 2003, 82:500-505.
15. Ghobrial I.M., Bone N.D., Stenson M.J., Novak A., Hedin K.E., Kay N.E., et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clinic Proceedings 2004, 79:318-325.
16. Herishanu Y., Perez-Gelen P., Liu D., Biancotto A., Vire B., Gibellini F., et al. Comparative gene expression profiling of leukemia cells in peripheral blood and tissue compartments reveals a prominent role of the microenvironment for CLL cell proliferation. Blood 2009, 114. [Abstract 355].
17. Bennett F., Rawstron A., Plummer M., de Tute R., Moreton P., Jack A., et al. B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. British Journal of Haematology 2007, 139:600-604.
18. Calissano C., Damle R.N., Hayes G., Murphy E.J., Hellerstein M.K., Moreno C., et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009, 114:4832-4842.
19. Till K.J., Lin K., Zuzel M., Cawley J.C. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002, 99:2977-2984.
20. Trentin L., Cabrelle A., Facco M., Carollo D., Miorin M., Tosoni A., et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004, 104:502-508.
21. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
22. Nishio M., Endo T., Tsukada N., Ohata J., Kitada S., Reed J.C., et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005, 106:1012-1020.
23. Richardson S.J., Matthews C., Catherwood M.A., Alexander H.D., Carey B.S., Farrugia J., et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:3584-3592.
24. Nagasawa T., Kikutani H., Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:2305-2309.
25. Quiroga M.P., Balakrishnan K., Kurtova A.V., Sivina M., Keating M.J., Wierda W.G., et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114:1029-1037.
26. Vlad A., Deglesne P.A., Letestu R., Saint-Georges S., Chevallier N., Baran-Marszak F., et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Research 2009, 69:6387-6395.
27. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
28. Deaglio S., Vaisitti T., Aydin S., Bergui L., D'Arena G., Bonello L., et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007, 110:4012-4021.
29. Vaisitti T., Aydin S., Rossi D., Cottino F., Bergui L., D'Arena G., et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010, 24:958-969.
30. Burger M., Hartmann T., Krome M., Rawluk J., Tamamura H., Fujii N., et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005, 106:1824-1830.
31. Niedermeier M., Hennessy B.T., Knight Z.A., Henneberg M., Hu J., Kurtova A.V., et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009, 113:5549-5557.
32. Kurtova A.V., Balakrishnan K., Chen R., Ding W., Schnabl S., Quiroga M.P., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114:4441-4450.
33. Rawstron A.C., Kennedy B., Evans P.A., Davies F.E., Richards S.J., Haynes A.P., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
34. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
35. Andritsos L.A., Byrd J.C., Hewes B., Kipps T.J., Johns D., Burger J.A. Preliminary results from a phase I/II dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Haematologica 2010, 95. [Abstract 0772].
36. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
37. Advani R., Sharman J.P., Smith S.M., Pollyea D.A., Boyd T.E., Grant B.W., et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study. Journal of Clinical Oncology 2010, 8012a.
38. Flinn I.W., Byrd J.C., Furman R.R., Brown J.R., Benson D.M., Coutre S.E., et al. Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110 isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies. Blood 2009, 114:380a.
39. de Gorter D.J., Beuling E.A., Kersseboom R., Middendorp S., van Gils J.M., Hendriks R.W., et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007, 26:93-104.
40. Cinamon G., Zachariah M.A., Lam O.M., Foss F.W., Cyster J.G. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nature Immunology 2008, 9:54-62.
41. Muller G., Hopken U.E., Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunological Reviews 2003, 195:117-135.
42. Dobner T., Wolf I., Emrich T., Lipp M. Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma. European Journal of Immunology 1992, 22:2795-2799.
43. Forster R., Mattis A.E., Kremmer E., Wolf E., Brem G., Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996, 87:1037-1047.
44. Gunn M.D., Ngo V.N., Ansel K.M., Ekland E.H., Cyster J.G., Williams L.T. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998, 391:799-803.
45. Allen C.D., Ansel K.M., Low C., Lesley R., Tamamura H., Fujii N., et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nature Immunology 2004, 5:943-952.
46. Allen C.D., Okada T., Tang H.L., Cyster J.G. Imaging of germinal center selection events during affinity maturation. Science (New York, NY) 2007, 315:528-531.
47. Schwickert T.A., Lindquist R.L., Shakhar G., Livshits G., Skokos D., Kosco-Vilbois M.H., et al. In vivo imaging of germinal centres reveals a dynamic open structure. Nature 2007, 446:83-87.
48. Bajenoff M., Egen J.G., Koo L.Y., Laugier J.P., Brau F., Glaichenhaus N., et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006, 25:989-1001.
49. Hardy R.R. B-1 B cell development. Journal of Immunology 2006, 177:2749-2754.
50. Caligaris-Cappio F., Gobbi M., Bofill M., Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. The Journal of Experimental Medicine 1982, 155:623-628.
51. Ishikawa S., Sato T., Abe M., Nagai S., Onai N., Yoneyama H., et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. The Journal of Experimental Medicine 2001, 193:1393-1402.
52. Ansel K.M., Harris R.B., Cyster J.G. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002, 16:67-76.
53. Berberich S., Forster R., Pabst O. The peritoneal micromilieu commits B cells to home to body cavities and the small intestine. Blood 2007, 109:4627-4634.
54. Jones D., Benjamin R.J., Shahsafaei A., Dorfman D.M. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000, 95:627-632.
55. Lopez-Giral S., Quintana N.E., Cabrerizo M., Alfonso-Perez M., Sala-Valdes M., De Soria V.G., et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. Journal of Leukocyte Biology 2004, 76:462-471.
56. Burkle A., Niedermeier M., Schmitt-Graff A., Wierda W.G., Keating M.J., Burger J.A. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007, 110:3316-3325.
57. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Reviews. Immunology 2006, 6:205-217.
58. Luther S.A., Lopez T., Bai W., Hanahan D., Cyster J.G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000, 12:471-481.
59. Lacotte S., Brun S., Muller S., Dumortier H. CXCR3, inflammation, and autoimmune diseases. Annals of the New York Academy of Sciences 2009, 1173:310-317.
60. Loetscher M., Loetscher P., Brass N., Meese E., Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. European Journal of Immunology 1998, 28:3696-3705.
61. Trentin L., Agostini C., Facco M., Piazza F., Perin A., Siviero M., et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. The Journal of Clinical Investigation 1999, 104:115-121.
62. Ocana E., Delgado-Perez L., Campos-Caro A., Munoz J., Paz A., Franco R., et al. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 2007, 92:349-356.
63. Forster R., Davalos-Misslitz A.C., Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nature Reviews. Immunology 2008, 8:362-371.
64. Shields J.D., Fleury M.E., Yong C., Tomei A.A., Randolph G.J., Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007, 11:526-538.
65. Hopken U.E., Winter S., Achtman A.H., Kruger K., Lipp M. CCR7 regulates lymphocyte egress and recirculation through body cavities. Journal of Leukocyte Biology 2010, 87:671-682.
66. Redondo-Munoz J., Jose Terol M., Garcia-Marco J.A., Garcia-Pardo A. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 2008, 111:383-386.
67. Cuesta-Mateos C., Lopez-Giral S., Alfonso-Perez M., Garcia de Soria V.G., Loscertales J., Guasch-Vidal S., et al. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines Ccl19 and Ccl21 in B-chronic lymphocytic leukemia. Experimental Hematology 2010, 38:756-764.
68. Alfonso-Perez M., Lopez-Giral S., Quintana N.E., Loscertales J., Martin-Jimenez P., Munoz C. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. Journal of Leukocyte Biology 2006, 79:1157-1165.
69. Schall T.J., Bacon K., Camp R.D., Kaspari J.W., Goeddel D.V. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. The Journal of Experimental Medicine 1993, 177:1821-1826.
70. Krzysiek R., Lefevre E.A., Zou W., Foussat A., Bernard J., Portier A., et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. Journal of Immunology 1999, 162:4455-4463.
71. Alizadeh A., Eisen M., Davis R.E., Ma C., Sabet H., Tran T., et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor Symposia on Quantitative Biology 1999, 64:71-78.
72. Eberlein J., Nguyen T.T., Victorino F., Golden-Mason L., Rosen H.R., Homann D. Comprehensive assessment of chemokine expression profiles by flow cytometry. The Journal of Clinical Investigation 2010, 120:907-923.
73. Shaffer A.L., Yu X., He Y., Boldrick J., Chan E.P., Staudt L.M. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000, 13:199-212.
74. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
75. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine 2002, 346:1937-1947.
76. Lossos I.S., Czerwinski D.K., Alizadeh A.A., Wechser M.A., Tibshirani R., Botstein D., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. The New England Journal of Medicine 2004, 350:1828-1837.
77. Roussou M., Tasidou A., Dimopoulos M.A., Kastritis E., Migkou M., Christoulas D., et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009, 23:2177-2181.
78. Terpos E., Politou M., Szydlo R., Goldman J.M., Apperley J.F., Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology 2003, 123:106-109.
79. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
80. Zucchetto A., Benedetti D., Tripodo C., Bomben R., Dal Bo M., Marconi D., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Research 2009, 69:4001-4009.
81. Palacios F., Moreno P., Morande P., Abreu C., Correa A., Porro V., et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 2010, 115:4488-4496.
82. Hamed H., Zaki S. Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy. The Egyptian Journal of Immunology/Egyptian Association of Immunologists 2007, 14:63-72.
83. Deaglio S., Vaisitti T., Bergui L., Bonello L., Horenstein A.L., Tamagnone L., et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005, 105:3042-3050.
84. Burger J.A., Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood 2009, 114:2560-2561. [author reply 1-2].
85. Penna G., Vulcano M., Roncari A., Facchetti F., Sozzani S., Adorini L. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. Journal of Immunology 2002, 169:6673-6676.
86. Bystry R.S., Aluvihare V., Welch K.A., Kallikourdis M., Betz A.G. B cells and professional APCs recruit regulatory T cells via CCL4. Nature Immunology 2001, 2:1126-1132.
87. Castellino F., Huang A.Y., Altan-Bonnet G., Stoll S., Scheinecker C., Germain R.N. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895.
88. Ghia P., Strola G., Granziero L., Geuna M., Guida G., Sallusto F., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. European Journal of Immunology 2002, 32:1403-1413.
89. Patten P.E., Buggins A.G., Richards J., Wotherspoon A., Salisbury J., Mufti G.J., et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111:5173-5181.
90. Tsukada N., Burger J.A., Zvaifler N.J., Kipps T.J. Distinctive features of " nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030-1037.
91. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
92. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research 2009, 69:2000-2009.
93. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Research 2006, 66:5716-5722.
94. Luqman M., Klabunde S., Lin K., Georgakis G.V., Cherukuri A., Holash J., et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008, 112:711-720.
95. Binsky I., Haran M., Starlets D., Gore Y., Lantner F., Harpaz N., et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:13408-13413.
96. Wierda W.G., Johnson M.M., Do K.A., Manshouri T., Dey A., O'Brien S., et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. British Journal of Haematology 2003, 120:452-456.
97. Sipkins D.A., Wei X., Wu J.W., Runnels J.M., Cote D., Means T.K., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005, 435:969-973.
98. Mackay C.R. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nature Immunology 2008, 9:988-998.